

Instructions for Use

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

AN ASSAY KIT FOR THE DETECTION OF *CHLAMYDIA TRACHOMATIS* AND *UREAPLASMA UREALYTICUM* DNA BY REAL-TIME PCR










In vitro Diagnostics



RealLine Chlamydia trachomatis / Ureaplasma urealyticum (Fla-Format)	VBD0491	100 Tests
valid from	September 2019	

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

Explanation of symbols used in labeling

	<i>In vitro</i> diagnostic medical device
	Batch code
	Catalogue number
	Contains sufficient for <n> tests
	Use-by-date
	Temperature limit
	Consult instructions for use
	Keep away from sunlight
	Manufacturer



BIORON Diagnostics GmbH

In den Rauhweiden 20
67354 Römerberg
Germany

Phone +49 6232 298 44 0

Fax: +49 6232 298 44 29

info@bioron.de

Trademarks:

Rotor-Gene® is a registered trademark of Qiagen Group, Germany.

**RealLine Chlamydia trachomatis /
Ureaplasma urealyticum
Fla-Format**

Table of content:

1. INTRODUCTION AND INTENDED USE	4
2. KIT CONTENTS	6
3. PRINCIPLE OF THE METHOD	6
4. SPECIFICATIONS	7
5. LIMITATIONS	8
6. WARNING AND PRECAUTIONS	9
7. ADDITIONAL MATERIALS AND DEVICES REQUIRED BUT NOT SUPPLIED	9
8. PREPARATION OF THE SPECIMEN	10
9. PROCEDURE	11
10. DATA ANALYSIS AND INTERPRETATION	13
11. STORAGE AND TRANSPORTATION	13
12. REFERENCES	15
ANNEX I: Settings for RealLine Cyclers and DT96:	16
ANNEX II: Programming the device and analysis of results using Rotor-Gene cyclers:	17

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

AN ASSAY KIT FOR THE DETECTION OF *CHLAMYDIA TRACHOMATIS* AND *UREAPLASMA UREALYTICUM* DNA BY REAL-TIME PCR

In vitro Diagnostics

1. INTRODUCTION AND INTENDED USE

1.1. Pathogen information

Chlamydia trachomatis is a Gram-negative, ovoid, non-motile bacterium from the genus *Chlamydia*. It is an obligate intracellular parasite, for which humans are the only host [1]. Chlamydia is one of the most common sexually transmitted diseases worldwide. Infections are most common among those between the ages of 15 and 25 and are more common in women than men. The young women have the highest prevalence of genitourinary *C. trachomatis* infections. Most infected women (more than 70%) and about 50% of infected men are asymptomatic [2]. Women infected with chlamydia are up to three times more likely to become infected with HIV, if exposed [3]. In men, the most common manifestation of *C. trachomatis* infection is inflammation of the urethra (about 50% of cases) [4]. The untreated infection may result in epididymitis, which in some cases can lead to fertility problems. Neonates born of infected mothers can develop inclusion conjunctivitis, nasopharyngeal infections and pneumonia due to *C. trachomatis* [5].

Definitive diagnosis is very important for infected person and his/her partner(s). As many people in the population are infected and the significant proportion of infection is asymptomatic, the diagnosis is often established by screening, which is recommended to perform regularly in sexually active young women, in other people from higher risk groups, and at the first prenatal visit [6]. Most *C. trachomatis* strains have a multicopy extrachromosomal cryptic plasmid, which is widely used as the target for PCR testing. As some *C. trachomatis* isolates are reported not to carry cryptic plasmid or have deletion(s) in it [7], "RealLine Chlamydia trachomatis/ Ureaplasma urealyticum" assay kit detects two DNA fragments from *gyrA* gene and cryptic plasmid, specific to *C. trachomatis* species.

Ureaplasma species are bacteria belonging to *Mycoplasmatacea* family that lack a cell wall and therefore cannot be seen on Gram stain. Species are subdivided into *U. parvum* (serotypes 1, 3, 6, and 14) and *U. urealyticum* (serotypes 2, 4, 5, and 7 through 13). These subtypes cannot be distinguished from each other with routine microbiological method. Differentiation might be important because nongonococcal urethritis and adverse pregnancy outcome with respect to birth weight, gestational age, and preterm delivery are suggested to be implicated with the presence of *U. urealyticum* and not with *U. parvum*.

Ureaplasma spp. are detected in the vaginal flora of 40-80% of sexually active women and may cause urethritis and cystitis. Horizontal transmission is by sexual contact and genital infection is usually asymptomatic. The vertical transmission rate varies from 18 to 88% in different studies. Babies can be infected by intrauterine infection or intrapartum transmission. Newborns infected with *U. urealyticum* were subject to more frequent and longer therapeutic procedures supporting respiration, needed more frequent surfactant and antibiotic administration. *U. urealyticum* and *U. parvum* may also cause neonatal infections, including meningoencephalitis and pneumonia.

In men, although genital tract infection is usually asymptomatic, *U. urealyticum* is one of the most common pathogens associated with male infertility and is isolated in 76% of infertile men compared with 19% of fertile men. In addition, *Ureaplasma spp.* have been reported to cause unusual infections, such as prosthetic joint infection and infections in transplant recipients. Although rare,

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

invasive *Ureaplasma* infection (meningitis, renal abscess, mediastinitis and arthritis) has also been reported in both adults and children [8-17]. “RealLine Chlamydia trachomatis / Ureaplasma urealyticum” assay kit detects the fragment of the urease enzyme gene, which is highly conserved in all *Ureaplasma* species. Primers and probe in the kit are designed for better discrimination between species *U. urealyticum* and *U. parvum*, none of cross-specific reactions has been observed.

1.2. Intended use

RealLine Chlamydia trachomatis / Ureaplasma urealyticum kit is intended for the detection of *Chlamydia trachomatis* and *Ureaplasma urealyticum* DNA in clinical specimens:

urine, swabs of the epithelial cells, semen, prostate fluid.

The assay is based on real-time polymerase chain reaction (PCR) method with fluorescent detection of amplified product

The extraction of DNA from clinical materials can be performed using the extraction kits:

- **RealLine DNA-Express (REF VBC8899)**
- **RealLine DNA-Extraction 3 (REF VBC8889)**
- **RealLine Extraction 100 (REF VBC8896)**

When using DNA extraction kits of other manufacturers it is highly recommended to use Internal Control sample (IC) (VBC8881, BIORON Diagnostics)

The results of PCR analysis are taken into account in complex diagnostics of disease.

The **Fla-format Kit** of the kit is intended for use with rotor-type PCR cyclers: Rotor-Gene 3000/6000 (Corbett Research, Australia) and Rotor-Gene Q (Qiagen, Germany) and block-type PCR cyclers: iQ5 iCycler, CFX96 (Bio-Rad, USA), DT96 (DNA-Technology, Russia) and RealLine Cyclers 96 and 48 (BIORON Diagnostics GmbH).

The **Fla-format Kit** contains 10 vials with the lyophilized Mastermix, each vial with 10 reactions, for volume of 50 µl per reaction. The kit contains reagents required for 100 tests, including control samples.

The use of:

- ! **Extraction Kits for nucleic acids from clinical specimen from other supplier**
- ! **other real-time PCR devices**
- ! **appropriate reaction volumes, other than 50 µl**

has to be validated in the lab by the user. The special notes regarding the internal control IC have to be strongly followed.

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

2. KIT CONTENTS

Universal Positive Control Sample (PC) -	1 vial, 1 ml
Master Mix for PCR (MM), lyophilized	10 tubes, 10 tests each
Recovery Solution (RS)	2 vials, 2 ml each

3. PRINCIPLE OF THE METHOD

Real-time PCR is based on the detection of the fluorescence, produced by a reporter molecule, which increases as the reaction proceeds. Reporter molecule is dual-labeled DNA-probe, which specifically binds to the target region of pathogen DNA. Fluorescent signal increases due to the fluorescent dye and quencher separating by Taq DNA-polymerase exonuclease activity during amplification. PCR process consists of repeated cycles: temperature denaturation of DNA, primer annealing and complementary chain synthesis.

Threshold cycle value - Ct – is the cycle number at which the fluorescence generated within a reaction crosses the fluorescence threshold, a fluorescent signal rises significantly above the background fluorescence. Increased fluorescence signal is due to the use of a specific for given DNA sequence DNA hybridization probe that in the course of reaction binds with one of the DNA strands, also providing additional specificity of the method. DNA probe comprises of a fluorescent dye at the 5' end and of fluorescence quencher at the 3' end which significantly reduces the fluorescence intensity. During the polymerase synthesis of the complementary strand, due to the 5'-3' nuclease activity of Taq DNA polymerase the probe is cleaved from the 5'-terminus and separation of the quencher and the dye occurs, resulting in the increase the fluorescence signal due to accumulation of the reaction product. Fluorescence intensity detected depends on initial quantity of pathogen DNA template in the sample.

The use of **Internal Control (IC)** prevents generation of false negative results associated with possible loss of DNA template during specimen preparation. IC indicates if PCR inhibitors occur in the reaction mixture. IC template should be added in each single sample (including control samples) prior to DNA extraction procedure. The amplification and detection of IC does not influence the sensitivity or specificity of the target DNA PCR.

Note: IC is a component of the DNA extraction kits of RealLine series. Internal Control is added to the specimen during DNA isolation step and is used throughout the whole process of DNA extraction, amplification, detection.

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

4. SPECIFICATIONS

4.1. Analytical Specificity:

The analytical specificity of “RealLine Chlamydia trachomatis / Ureaplasma urealyticum” assay kit is ensured by specific primers and probes. The primers and probes were checked for possible homologies to all sequences published in gene banks by sequence comparison analysis.

The analytical specificity of *Chlamydia trachomatis* DNA detection is determined on five samples containing 100 copies of *Ureaplasma urealyticum* DNA, as a percentage of the samples determined by the kit as negative.

The analytical specificity of *Ureaplasma urealyticum* DNA detection is determined on five samples containing 100 copies of *Chlamydia trachomatis* DNA, as a percentage of the samples determined by the kit as negative. Specificity of *Chlamydia trachomatis* and *Ureaplasma urealyticum* DNA detection equals 100%.

4.2. Analytical Sensitivity:

The analytical sensitivity of *Chlamydia trachomatis* DNA detection is determined on 5 samples, containing 100 copies of *Chlamydia trachomatis* DNA per sample prepared from *Chlamydia trachomatis* DNA Standard Reference Sample (SRS), as percentage of samples detected by the kit as positive. Sensitivity equals 100 %.

The analytical sensitivity of *Ureaplasma urealyticum* DNA detection is determined on five samples, containing 100 copies of *Ureaplasma urealyticum* DNA per sample prepared from *Ureaplasma urealyticum* DNA Standard Reference Sample (SRS), as percentage of samples detected by the kit as positive. Sensitivity equals 100 %.

4.3. Diagnostic Evaluation:

Diagnostic sensitivity of *Chlamydia trachomatis* DNA detection: clinical tests conducted on 55 positive samples (29 epithelial cells swabs from the patients infected with *Chlamydia trachomatis*; 26 epithelial cells swabs from the patients infected with *Chlamydia trachomatis* and *Ureaplasma urealyticum*) showed 100 % sensitivity (interval 94.7 % - 100 %, with a confidence level of 90 %).

Diagnostic sensitivity of *Ureaplasma urealyticum* DNA detection: clinical tests conducted on 63 positive samples (37 epithelial cells swabs from the patients infected with *Ureaplasma urealyticum*; 26 epithelial cells swabs from the patients infected with *Chlamydia trachomatis* and *Ureaplasma urealyticum*) showed 100 % sensitivity (interval 95.4 % - 100 %, with a confidence level of 90 %).

Diagnostic specificity of *Chlamydia trachomatis* DNA detection: clinical tests conducted on 133 negative samples (50 epithelial cells swabs from healthy donors; 46 epithelial cells swabs from patients infected with *Mycoplasma genitalium*, *Mycoplasma hominis*, *Trichomonas vaginalis*; 37 epithelial cells swabs from the patients infected with *Ureaplasma urealyticum*) showed 100 % specificity (interval 97.8 % - 100 %, confidence level of 90 %).

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

Diagnostic specificity of *Ureaplasma urealyticum* DNA detection: clinical tests conducted on 125 negative samples (50 epithelial cells swabs from healthy donors; 46 epithelial cells swabs from patients infected with *Mycoplasma genitalium*, *Mycoplasma hominis*, *Trichomonas vaginalis*; 29 epithelial cells swabs from the patients infected with *Chlamydia trachomatis*) showed 100 % specificity (interval 97.6 % - 100 %, confidence level of 90 %).

Analysis by the CE-marked reference kit showed full match of results.

5. LIMITATIONS

- This assay must not be used on the clinical specimen directly. Appropriate nucleic acids extraction methods have to be conducted prior to using this assay.
- The presence of PCR inhibitors (e.g. heparin) may cause false negative or invalid results.
- When monitoring a patient the same extraction method must be used in all determinations. Otherwise, results may not be relative.
- The kit is intended to be used for supporting the diagnosis of *C. trachomatis* / *U. urealyticum* infection and should be interpreted with consideration of clinical and laboratory findings.
- Diagnostic sensitivity of the kit may vary depending on the pathogen prevalence and characteristics of the enrolled cohort.
- Reliable results depend on adequate specimen sampling.
- Positive results indicate active or asymptomatic infection; results should be interpreted with consideration of clinical and laboratory findings.
- Negative results indicate lack of detectable DNA but do not exclude the infection or disease.
- Potential mutations within the target regions of the *C. trachomatis* and *M. genitalium* genome covered by the primers and/or probes used in the kit may result in failure to detect the presence of the pathogens.
- The kit is not intended to replace culture and other methods (e.g., cervical exam) for diagnosis of urogenital infection.

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

6. WARNING AND PRECAUTIONS

- ☞ For in vitro use only.
- ☞ The kits must be used by skilled personnel only.
- ☞ When handling the kit, follow the national safety requirements for working with pathogens.
- ☞ To prevent contamination, the stages of DNA extraction and PCR test run must be spatially separated.
- ☞ Avoid microbial and ribonuclease contamination of reagents when removing aliquots from reagent vials.
- ☞ Wear protective disposable gloves, laboratory coats and eye protection when handling specimens and kit reagents.
- ☞ Every workplace must be provided with its own set of variable-volume pipettes, necessary auxiliary materials and equipment. It is prohibited to relocate them to other workplaces.
- ☞ The use of sterile disposable pipette tips is recommended.
- ☞ Never use the same tips for different samples.
- ☞ Do not pool reagents from different lots or from different vials of the same lot.
- ☞ Dispose unused reagents and waste in accordance with country, federal, state and local regulations.
- ☞ Do not use the kit after the total expiration date at the side label of the box.

7. ADDITIONAL MATERIALS AND DEVICES REQUIRED BUT NOT SUPPLIED

- Real time PCR system, like described in p.1.2.
- DNA-Extraction Kit: **RealLine DNA-Express**, **RealLine DNA-Extraction 3** or **RealLine Extraction 100**
- Internal Control reagent (VBC8881) and Negative Control Sample, if the kit is used with the extraction kits of other supplier.
- Plates or tubes suitable for the used device with caps or a sealing foil for PCR
- Laminar safety box;
- Refrigerator;
- Microcentrifuge;
- Half-automatic variable-volume single-channel pipettes;
- Disposable medical non-sterile powder-free gloves;
- Disposable pipette tips with aerosol filter;
- Biohazard waste container;
- Scalpel or razor
- Racks for 2 ml and 0.2 ml tubes

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

8. PREPARATION OF THE SPECIMEN

The assay is performed on extracted DNA samples obtained from the clinical material using one of the DNA extraction kits listed in p.1.2, according to the Instruction Manual to the kit. If an extraction kit with magnetic particles is used, keep the tubes with extracted DNA in the magnetic rack.

Each group of samples undergoing the procedure of DNA isolation must include a **Positive Control sample (PC)** from this kit and a **Negative Control sample (NC)** which is a component of the DNA extraction kit.

We strongly recommend the implementation of the Internal Control IC, the Negative Control NC and Positive Control PC samples to the extraction procedure.

When using kits of another supplier for the extraction of nucleic acids as recommended in chapter 1: add **20 µl** of **IC (VBC8881)** to each tube.

- For the NC use **100 µl** of the Negative Control Sample
- For the PC use **70 µl** of Negative Control Sample and **30 µl** of Positive Control to the tube marked PC.

If samples of isolated DNA were stored frozen prior the assay, thaw them and keep at least 30 minutes at a temperature of (18 – 25) °C.

Store the extracted DNA at (2–8) °C for no more than 24 hours.

After initial opening, store Positive Control sample at (2 – 8) °C for no more than 1 month or in 50 µl aliquots 3 month at (-18 ... -24) °C for no more than 3 month.

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

9. PROCEDURE

9.1 Preparation of the Kit Components

Prior to the test, take the kit out of the refrigerator, open the package, take the necessary number of tubes with the **Master Mix for PCR (MM)**, taking into account prepared specimens and control samples. For each test 1 NC and 1 PC are required. Keep the tubes at (18 – 25) °C for at least 30 min. Put the remaining tubes immediately back into the foil pouch, squeeze the air out and tightly close with the clip.

Attention! Each tube with MM is intended for 10 tests.

After initial opening of the package, store MM at (2 – 8) °C for no more than 3 months.

To prepare diluted Master Mix, add **300 µl of Recovery Solution (RS)** to each tube with MM. Mix gently, keep at (18-25) °C for 15 min, and mix again.

Store diluted MM at (2 – 8) °C for no more than 7 days.

After initial opening, store RS at (2 – 8) °C for no more than 3 months.

9.2 Prepare an appropriate number of 0.2 ml tubes. Label each tube for each specimen and control sample.

Attention! Labels should be placed on the caps of tubes for rotor-type cyclers. For block-type cyclers labels should be placed on the lateral side of the tubes

9.3 Add **25 µl** of prepared Master Mix to each 0.2 ml tube.

9.4 Add **25 µl** of corresponding isolated DNA solution to each tube using a separate pipette tip with filter. Do not touch the pellet! Tightly close the tubes.

9.5 Place the tubes into the real-time PCR system.

9.6 Program real time PCR system as follows:

For Rotor-Gene® 3000 (6000, Q):

Step 1:	50°C	2 min	50 cycles
Step 2:	95°C	2 min	
Step 3:	94°C	10 sec	
	60°C*	40 sec	

* Measure the fluorescence at 60°C.

For RealLine Cycler, iQ™ iCycler, iQ™5 iCycler, CFX96™, DT-96:

Step 1:	50°C	2min	50 cycles
Step 2:	95°C	2min	
Step 3:	94°C	10 sec	
	60°C*	20 sec	

* Measure the fluorescence at 60°C

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

9.7 Select the amplification detection channels:

- Collect data through **FAM** channel (iQ5 iCycler, CFX96, RealLine Cyclers, DT-96, Rotor-Gene 3000) or **Green** channel (Rotor-Gene 6000, Rotor-Gene Q) for the detection of amplification signal of **IC DNA**;
- Collect data through **ROX** channel (iQ5 iCycler, CFX96, RealLine Cyclers, DT-96, Rotor-Gene 3000), and **Orange** channel (Rotor-Gene 6000, Rotor-Gene Q) for the detection of amplification signal of **Ureaplasma urealyticum** DNA;
- Collect data through **HEX** channel (iQ5 iCycler, CFX96, RealLine Cyclers, DT-96, Rotor-Gene 3000), and **JOE / Yellow** channel (Rotor-Gene 6000, Rotor-Gene Q) for the detection of amplification signal of **Chlamydia trachomatis** DNA;

9.8 Program the positions of test tubes with samples, positive and negative controls according to the instruction manual for the real time PCR system in use.

9.9 Run the program.

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

10. DATA ANALYSIS AND INTERPRETATION

10.1 For **Positive Control PC** the program should detect:

- Increase of the IC DNA amplification signal (channel **FAM / Green**) and determine the threshold cycle, **IC Ct**;
- Increase of the **Chlamydia trachomatis** DNA amplification signal (channel **HEX / JOE / Yellow**) and determine the **PC Ct** value;
- Increase of the **Ureaplasma urealyticum** DNA amplification signal (channel **ROX / Orange**) and determine the **PC Ct** value.

10.2 For **Negative Control NC** the program should detect the increase of the amplification signal of IC DNA (channel **FAM / Green**) and determine the threshold cycle, **IC Ct**. No **ROX / Orange** or **HEX / JOE / Yellow** fluorescent increase should appear (*no Chlamydia trachomatis or Ureaplasma urealyticum DNA amplification*).

10.3 For each sample the program should detect the increase of the amplification signal of IC DNA (channel **FAM / Green**) and determine **IC Ct**.

10.4 Calculate $(IC\ Ct)_{av}$ as an average **IC Ct** of all analyzed samples (including PC and NC). **IC Ct** values that differ by more than 2 from the $(IC\ Ct)_{av}$ should be ignored. Recalculate the $(IC\ Ct)_{av}$ for the remaining values after the screening.

10.5 The specimen is considered **positive**, i.e. containing **Ureaplasma urealyticum DNA**, if **Ct** value through **ROX / Orange** channel for this specimen is **less than or equals to 40**.

The specimen is considered **positive**, i.e. containing **Chlamydia trachomatis DNA**, if **Ct** value through **HEX / JOE / Yellow** channel for this specimen is **less than or equals to 40**.

10.6 The specimen is considered negative, if **Ct** value through **ROX / Orange** and **HEX / JOE / Yellow** channels for this specimen is **above 40 or is not determined**. If **IC Ct** value for such specimen differs from the $(IC\ Ct)_{av}$ value by more than 2, the result is regarded as **equivocal**. A repeated analysis of the specimen, starting from the DNA extraction step is required.

10.7 If **Ct** value for NC through **ROX / Orange** or **HEX / JOE / Yellow** channel is **less than or equal to 40**, it indicates the presence of contamination. In this case, all positive results of this individual PCR run are considered **equivocal**. Actions are required to identify and eliminate the source of contamination. Repeat the analysis of all specimens of this run that were identified as positive. Specimens that showed negative results in this run should be considered negative.

11. STORAGE AND TRANSPORTATION

- Store the assay kit at (2 - 8) °C in the manufacturer's packing.

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

- Transport at (2 - 8) °C . Transportation for up to 25 °C for up to 10 days is allowed.
- Do not freeze the kit!
- Do not pool reagents from different lots or from different vials of the same lot.
- Strictly follow the Instruction manual for reliable results.
- Do not use kits with damaged inner packages and get in contact with BIORON Diagnostics GmbH.

Storage and shelf life of solutions and components of the kit after initial opening:

Positive Control sample: 1 month at (2 - 8) °C *or in 50 µl aliquots at minus (18 - 60) °C for up to 3 months.*

Ready Master Mix (MM): unused MM at (2 - 8) °C for no more than 3 months

Diluted MM: at (2 - 8) °C for 7 days in a dark surrounding

Recovery Solution: at (2 - 8) °C for 3 months.

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

12. REFERENCES

1. Graeter L. Elsevier's Medical Laboratory Science Examination Review. Elsevier Health Sciences. 2014. p. 30. ISBN 9780323292412.
2. Manavi K. A review on infection with *Chlamydia trachomatis*. *Best Practice & Research. 2006. Clinical Obstetrics & Gynaecology*, 20, 941-951.
3. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. 2008. *Sex Transm Dis*, 35, 946-959.
4. NHS Chlamydia page, <https://www.nhs.uk/conditions/chlamydia/>
5. Alexander ER, Harrison HR. Role of *Chlamydia trachomatis* in perinatal infection. 1983. *Rev Infect Dis*, 5, 713-719.
6. Mishori R, McClaskey EL, Winkleprins VJ. Chlamydia Trachomatis Infections: Screening, Diagnosis, and Management. 2012. *American Family Physician*, 86, 12.
7. Ripa T, Nilsson P. A variant of *Chlamydia trachomatis* with deletion in cryptic plasmid: implications for use of PCR diagnostic tests. 2006. *Euro Surveill*, 11, E061109. 2 17213548.
8. Abele-Horn M, Wolff C, Dressel P, Pfaff F, Zimmermann A. Association of *Ureaplasma urealyticum* biovars with clinical outcome for neonates, obstetric patients, and gynecological patients with pelvic inflammatory disease. 1997. *J Clin Microbiol*, 35, 1199-1202.
9. Biernat-Sudolska M, Rojek-Zakrzewska D, Rzepecka-Weglarz B, Wozniak J, Lauterbach R. Influence of ureaplasma infection on the clinical state of newborns. 2006. *Przegl Epidemiol*, 60, 53-58.
10. Gdoura R, Kchaou W, Chaari C, Znazen A, Keskes L, Rebai T, Hammami A. *Ureaplasma urealyticum*, *Ureaplasma parvum*, *Mycoplasma hominis* and *Mycoplasma genitalium* infections and semen quality of infertile men. 2007. *BMC Infect Dis*, 7, 129.
11. Gwee A, Curtis N. Ureaplasma - Are you sitting comfortably? 2014. *J Infect*, 68, Suppl 1, 19-23.
12. Kataoka S, Yamada T, Chou K, Nishida R, Morikawa M, Minami M, Yamada H, Sakuragi N, Minakami H. Association between pre term birth and vaginal colonization by mycoplasmas in early pregnancy. 2006. *J Clin Microbiol*, 44, 51-55.
13. Robertson JA, Stemke GW, Davis JW, Jr, Harasawa R, Thirkell D, Kong F, Shepard MC, Ford DK. Proposal of *Ureaplasma parvum* sp. nov. and emended description of *Ureaplasma urealyticum* (Shepard et al. 1974) Robertson et al. 2001. 2002. *Int J Syst Evol Microbiol*, 52, 587-597.
14. Wang Y, Liang CL, Wu JQ, Xu C, Qin SX, Gao ES. Do *Ureaplasma urealyticum* infections in the genital tract affect semen quality? 2006. *Asian J Androl*, 8, 562-568.
15. Yoshida T, Deguchi T, Meda S, Kubota Y, Tamaki M, Yokoi S, Yasuda M, Ishiko H. Quantitative detection of *Ureaplasma parvum* (biovar 1) and *Ureaplasma urealyticum* (biovar 2) in urine specimens from men with and without urethritis by real-time polymerase chain reaction. 2007. *Sex Transm Dis*, 34, 416-419.
16. Yokoi S, Maeda S, Kubota Y, Tamaki M, Mizutani K, Yasuda M, Ito S, Nakano M, Ehara H, Deguchi T. The role of *Mycoplasma genitalium* and *Ureaplasma urealyticum* biovar 2 in postgonococcal urethritis. 2007. *Clin Infect Dis*, 45, 866-871.

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

17. Zeighami H, Peerayeh SN, Yazdi RS, Sorouri R. Prevalence of *Ureaplasma urealyticum* and *Ureaplasma parvum* in semen of infertile and healthy men. 2009. *Int J STD AIDS*, 20, 387-390.

ANNEX I: Settings for RealLine Cyclers and DT96:

for these cyclers the measurement exposure must be adjusted. Choose the **Operation with the device** mode in the **Settings** menu, select the item **Measurement exposition:**

- **FAM** to **250**
- **HEX** and **ROX** to **1000**

Confirm that the current exposure value is saved by pressing **YES**

Attention! The specified exposure values are applicable only for RealLine kits and, if necessary, must be changed for other purposes.

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

ANNEX II: Programming the device and analysis of results using Rotor-Gene cyclers:

Rotor-Gene 3000, Rotor-Gene 6000 (Corbett research, Australia), Rotor-Gene Q (Qiagen, Germany)

Hereinafter, detection channels and terms corresponding to different versions of devices and software are listed in the following order: Rotor-Gene 3000 (Rotor-Gene 6000, Rotor-Gene Q).

- 1) Click **New** button.
- 2) Select an **Advanced** template from the tab of the New Run wizard. Click **New** button.
- 3) Select **36-Well Rotor** type, check that No Domed 0.2 ml Tubes are used. Click **Next** button.
- 4) In the new window, determine Reaction volume as **50 µl**. Click **Next** button.
- 5) The temperature profile of real time PCR should be set. Click **Edit Profile** button.

Step 1:	50°C	2min	50 cycles
Step 2:	95°C	2min	
Step 3:	94°C	10 sec	
	60°C*	40 sec	
- * Measure the fluorescence at 60°C
- 6) Then temperature profile is set, click **OK** button.
- 7) In the **New Run Wizard** window click **Calibrate (Gain optimization)** button. The window **Auto Gain Calibration Setup** opens. In the line **Channel Settings** choose **ROX (Orange)**, click **Add**. Set **Tube Position 1, Min Reading 5, Max Reading 10**, click **OK**. In the line **Channel Settings** choose **JOE (Yellow)**, click **Add**. Set **Tube Position 1, Min Reading 5, Max Reading 10**, click **OK**. In the line **Channel Settings** choose **FAM (Green)**, click **Add**. Set **Tube Position 1, Min Reading 5, Max Reading 10**, click **OK**.
- 8) Tick off **Perform Calibration Before 1st Acquisition**. Click **Close** button.
- 9) Click **Next** button, start the amplification process by clicking **Start Run** button.
- 10) Save a file in the Rotor-Gene/templates folder, named RealLine with *.ret extension. In subsequent work RealLine template would be presented in New run wizard.
- 11) Save reaction result file with Rotor-Gene Run File *.rex extension.
- 12) Record the positions of the controls and specimens according to the instruction manual of the operating device. Click **Start run** button.

Results of IC DNA amplification

- 1) Click **Analysis** button, choose **Quantitation** from the list, choose **Cycling A. FAM («Cycling A. Green»)**, click **Show** button.
- 2) Click **OK** button, and cancel automatic **Threshold** determination.
- 3) Click **Linear scale** button. Settings should change to **Log. scale**.
- 4) In the **Quantitation analysis** menu buttons **Dynamic tube** and **Slope Correct** should be pressed.
- 5) Click **More Settings (Outlier Removal)** button, determine **NTC threshold** value as **5 %**.
- 6) In the column **CT Calculation (right part of the window)** determine **Threshold** value as **0.04**.
- 7) In the result table (**Quant. Results window**) **Ct** will be displayed.

RealLine Chlamydia trachomatis / Ureaplasma urealyticum Fla-Format

Results of *Chlamydia trachomatis* DNA amplification

- 1) Click **Analysis** button, choose **Quantitation** from the list, choose **Cycling A. JOE** (*Cycling A. Yellow*) click, **Show** button.
- 2) Click **OK** button, and cancel automatic **Threshold** determination.
- 3) Click **Linear scale** button. Settings should change to **Log. scale**.
- 4) In the **Quantitation analysis** menu buttons **Dynamic tube** and **Slope Correct** should be pressed.
- 5) Click **More Settings** (*Outlier Removal*) **button**, determine **NTC threshold** value as **10%**.
- 6) In the column **CT Calculation** (*right part of the window*) determine **Threshold** value as **0.04**.
- 7) In the result table (*Quant. Results window*) Ct will be displayed.

Results of *Ureaplasma urealyticum* DNA amplification

- 1) Click **Analysis** button, choose **Quantitation** from the list, choose **Cycling A. ROX** (*Cycling A. Orange*) click, **Show** button.
- 2) Click **OK** button, and cancel automatic **Threshold** determination.
- 3) Click **Linear scale** button. Settings should change to **Log. scale**.
- 4) In the **Quantitation analysis** menu buttons **Dynamic tube** and **Slope Correct** should be pressed.
- 5) Click **More Settings** (*Outlier Removal*) **button**, determine **NTC threshold** value as **5 %**.
- 6) In the column **CT Calculation** (*right part of the window*) determine **Threshold** value as **0.04**.
- 7) In the result table (*Quant. Results window*) Ct will be displayed.

Technical Support: techsupport@bioron.de

**RealLine Chlamydia trachomatis /
Ureaplasma urealyticum
Fla-Format**

RealLine Pathogen Diagnostic Kits

**RealLine Chlamydia trachomatis /
Ureaplasma urealyticum
Fla-Format**

